OBJECTIVES: Epidemiologic data suggest older adults receiving serotonergic antidepressants may have accelerated bone loss. We examined bone turnover marker changes and patient-level variables associated with these changes in older adults receiving protocolized antidepressant treatment. DESIGN: Open-label, protocolized treatment study. SETTING: Medical centers in Pittsburgh, St Louis, and Toronto. PARTICIPANTS: Older adults with major depression (N = 168). MEASUREMENTS: Serum levels of the bone resorption marker C-terminal cross-linking telopeptide of type 1 collagen (CTX) and the bone formation marker procollagen type 1 N propeptide (P1NP) were assayed before and after 12 weeks of treatment with venlafaxine. Whether CTX and P1NP changes were associated with depression remission and duration of depression and genetic polymorphisms in the serotonin transporter (5HTTLPR) and 1B receptor (HTR1B) were also examined. RESULTS: CTX increased and P1NP decreased during venlafaxine treatment, a profile consistent with accelerated bone loss. Two individual-level clinical variables were correlated with bone turnover; participants whose depression did not go into remission had higher CTX levels, and those with chronic depression had lower P1NP levels. HTR1B genotype predicted P1NP change, whereas 5HTTLPR genotype was unrelated to either biomarker. CONCLUSION: Bone turnover markers change with antidepressant treatment in a pattern that suggests accelerated bone loss, although the clinical significance of these changes is unclear. These data are preliminary and argue for a larger, controlled study to confirm whether antidepressants are harmful to bone metabolism and whether certain individuals might be at increased risk.
O ne in six older U.S. adults is prescribed an antidepressant, 1 typically serotonin reuptake inhibitors (SRIs) which include selective SRIs and serotonin-norepinephrine reuptake inhibitors. 2 SRIs block serotonin (5-HT) transporters, influencing 5-HT levels centrally and peripherally. 3 There are functional 5-HT receptors on bone cells, 3 and some studies have shown an association between SRIs and accelerated bone loss [4] [5] [6] in older adults. In a metaanalysis, use of selective SRIs was associated with 70% greater fracture risk. 7 Bone is a dynamic tissue, undergoing remodeling throughout the lifetime. 8 In the brain, SRIs inhibit 5-HT reuptake from the synapse, causing receptor and second messenger changes. 9, 10 Peripherally, SRIs alter gut-derived 5-HT levels, leading to downstream serotonergic effects on bone cells through the 5-HT transporter and the 5-HT receptor HTR1B. 11 Peripheral 5-HT inhibits osteoblast proliferation by binding to HTR1B on pre-osteoblasts and inactivating CREB, a transcription factor, possibly resulting in low bone mass. 3, 11 Genetic variation in 5-HT polymorphisms might modulate the brain and peripheral effects of SRIs. 5, 9, [12] [13] [14] In spite of these putative biological pathways, it is unknown whether SRIs influence bone health or whether the epidemiological findings reflect effects of depression itself, 5, 15, 16 although a preclinical study suggested a relationship between SRIs and bone loss. 17 Bone turnover markers were previously assessed in 77 older adults during an antidepressant clinical trial, 18 and it was found that C-terminal cross-linking telopeptide of type 1 collagen (CTX), a marker of osteoclast activity and bone resorption, significantly increased during treatment with the SRI venlafaxine. Procollagen type 1 N-propeptide (P1NP), a marker of osteoblast activity and bone formation, decreased. These changes were associated with treatment outcomes; participants whose depression remitted with the antidepressant treatment had minimal changes in their bone turnover markers, so it appeared that successful antidepressant response mitigated these bone turnover changes. Genetic variation in 5-HT polymorphisms as predictors of bone loss was also examined, and less bone formation was found in high-expressing 5HTTLPR (in the 5-HT transporter) and low-expressing HTR1B carriers. 12 It was concluded that bone turnover markers change during SRI treatment in a pattern suggestive of increasing bone loss, with clinical and genetic modulators of this effect.
In the current analysis, data from the 73 participants previously analyzed were combined with data from an additional 95 participants in whom CTX and P1NP was also assayed before and after venlafaxine treatment. The larger sample of 168 provides greater power to examine whether CTX increases and P1NP decreases with venlafaxine, these changes are more pronounced in participants who do not experience remission of depressive symptoms, and 5-HT polymorphisms modulate these changes. Other individual-level variables were also explored as predictors of biomarker changes.
METHODS

Participants
Participants were involved in the initial open-label phase of a three-site clinical trial: Incomplete Response to Late-Life Depression: Getting to Remission. 19 The sites' institutional review boards approved this study, and all participants provided written informed consent.
Participants were aged 60 and older and experiencing a major depressive episode at least 4 21 indicating at least moderate depressive symptoms. Exclusion criteria included bipolar or psychotic disorder, a diagnosis of dementia or a score less than 20 on the Mini-Mental Status Examination (MMSE) 22 , recent alcohol or substance abuse, and unstable medical comorbidities. Creatinine clearance levels were calculated as [140 À age] 9 weight (kg)/72 9 creatinine baseline level and multiplied by 0.85 for women.
Participants were also excluded from the current analyses who had been receiving a SRI within 2 weeks of baseline specimen collection, who had been taking bisphosphonates; who started or stopped a medication known for its effect on bone (corticosteroids, vitamin D, estrogen, calcium) during the trial, and whose serum was collected after 11:30 a.m. (to minimize diurnal variation). One additional participant was excluded because of severe renal impairment.
Treatment Protocol
Participants received open-label treatment with venlafaxine extended-release (XR). The initial dosage of 37.5 mg/d was titrated by 37.5-mg increments every 3 days to a target dosage of 150 mg/d by the end of the second week of treatment. The dosage of participants whose depression did not remit after 6 weeks of treatment was further titrated to a maximum dosage of 300 mg/d. Most participants received treatment for 12 weeks; a few received up to 12 additional weeks of treatment to clarify their remission status.
Participants were monitored closely throughout the trial, and dosage reductions were allowed at any time to manage side effects. Participants experiencing sleep disturbance or anxiety during the trial could be prescribed lorazepam (up to 2 mg/d) or continue previously prescribed sleep medications (e.g., zolpidem, zopiclone, trazodone).
Assessments
Baseline assessments included the MMSE (range 0-28) and the MADRS (range 0-60). Physical comorbidities were quantified using the Cumulative Illness Rating Scale for Geriatrics (range 0-52). 23 Follow-up visits occurred at 1, 2, 4, 6, 8, 10, and 12 weeks and included psychoeducation for depressive symptoms, monitoring of vital signs and adverse events, and assessment of depressive symptoms using the MADRS. Remission from depressive symptoms was defined as a MADRS score of 10 or less at the last two visits.
Sample Collection and Assays
Blood samples were collected between 8:30 a.m. and 11:30 a.m. after an overnight fast before venlafaxine treatment and at the last visit (typically after 12 weeks of treatment). Samples were immediately cold-centrifuged and stored at À80°C. Bone turnover markers were assayed at Core Diagnostics (School of Medicine, Washington University, St. Louis, MO) and included the Roche Diagnostics Elecsys kit for CTX and a radioimmunoassay for P1NP (Orion Diagnostica, Espoo, Flinland). Venlafaxine and Odesmethylvenlafaxine levels at the last study visit were assayed as previously described. 18 
Genotyping
Deoxyribonucleic acid was extracted and isolated from blood following standard procedures. The 5HTTLPR-rs25531 genotypes consist of an insertion-deletion motif designated as long (L)/short(S) element and an A/G single nucleotide polymorphism (SNP) at rs25531. These two variants are combined as Sa, Sg, La, and Lg, with the La combination conferring higher transcriptional activity to the serotonin transporter. For this analysis, the genotypes were consolidated, with the La/La, La/Lg, and La/S reflecting the four high-expressing activity genotypes and Lg/Lg, Lg/S, and S/S reflecting the low-expressing activity genotypes. 24 The serotonin receptor, HTR1B, has a SNP located in the promoter region at rs11568817; for analysis, GG and GT genotypes are marked as high expressing, and TT is marked as low expressing. 25 Five participants were missing data on HTTLPR and HTR1B, and five were missing data on HTTLPR only.
Statistical Analysis
Data from the additional 95 participants were combined with data from the 73 participants analyzed in the previous publication. 18 Standardized residual values for bone biomarker levels larger than AE3.29 were winsorized to the next value that fell within AE3.29 according to remission status. CTX and P1NP levels were log-transformed for statistical analysis modeling change. Using output from paired t-tests, the changes in bone biomarkers from baseline to end of treatment and changes associated with key predictor variables (remission status, gene polymorphisms) are reported on. Independent t-tests and chi-square tests were used to examine variable differences.
The relationships between key predictors and changes in bone biomarkers were next examined, holding possible confounding individual-level predictors constant using multivariable predictor models. Determination of confounding individual-level predictors first included examining separate regression models for each variable in Table 1 , controlling for baseline bone turnover marker levels, with end-of-treatment bone biomarker level as the outcome variable. Individual-level variables significant at P < .15, baseline biomarker levels, and remission status were included in the r-square selection model using Proc RSQUARE, an algorithm that calculates which variable combination best explains variation in an outcome. The variables from the model with the lowest Akaike Information Criterion were entered into a multivariable regression model. The multivariable regression models were repeated after nonwhite participants were excluded, and the two genetic predictors were added. Statistical analysis was conducted using SPSS version 22 (IBM Corp., Armonk, NY) and SAS version 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Participant Characteristics
The majority of the 168 participants (Table 1) were Caucasian (91.7%) and female (60.7%) and had a mean AE standard deviation age of 68.7 AE 6.8. Participants were typically healthy and cognitively intact and had moderate to severe depressive symptoms. Fifty-seven (33.9%) participants were taking bone-protective medications.
Bone Biomarker Changes During Treatment
Both bone turnover markers changed with venlafaxine treatment ( Figure 1) ; CTX levels (all numbers in text are log-transformed; figures show actual numeric values) significantly increased by an average of 0.06 AE 0.32 (t(167) = 2.3, P = .02; 55.4% had levels increase), and P1NP significantly decreased by an average of 0.05 AE 0.25 (t(165) = À2.5, P = .01; 60.7% had levels decrease).
Changes in Bone Turnover Markers According to Remission
The depression of 80 (47.6%) participants remitted with treatment, and that of 88 (52.4%) did not (Table 1) . For CTX, the mean increase was 0.09 AE 0.31 pg/mL (t (87) = 2.68, P = .009) for nonremitters and 0.02 AE 0.32 pg/ mL (t(79) = 0.49, P = .63) for remitters ( Figure 2A ). For P1NP, the mean decrease was 0.05 AE 0.25 lg/L (t (86) = À1.96, P = .053) for nonremitters and 0.04 AE 0.24 lg/L (t(78) = À1.49, P = .14) for remitters. These results did not change in multivariable regression analyses (Table S1 ) controlling for baseline biomarker levels and confounding individual-level variables; remission status remained correlated with end-of-treatment CTX levels (P = .008) but not end-of-treatment P1NP levels (P = .67).
Changes in Bone Biomarkers According to Genetic Polymorphisms
In the Caucasian subsample, 44 (29.5%) participants had a low-expressing HTR1B genotype and 41 (28.5%) had a low-expressing HTTLPR genotype. For CTX, the mean increase was 0.01 AE 0.29 pg/mL (t(43) = 0.26, P = .79) for HTR1B low expressers and 0.08 AE 0.31 pg/mL (t(104) = 2.53, P = .013) for high expressers. The mean increase in CTX was 0.02 AE 0.30 pg/mL (t(40) = 0.45, P = .66) for HTTLPR low expressers and 0.06 AE 0.31 pg/ mL (t(102) = 2.15, P = .03) for high expressers. For P1NP, the mean decrease was 0.09 AE 0.24 lg/L (t(43) = À2.47, P = .02) for HTR1B low-expressers and 0.04 AE 0.23 lg/L (t(102) = À1.83, P = .07) for high expressers ( Figure 2B ). The mean decrease in P1NP was 0.02 AE 0.29 lg/L (t(40) = À0.35, P = .73) for HTTLPR low expressers and 0.07 AE 0.21 lg/L (t(100) = À3.3, P = .001) for high expressers. Controlling for baseline biomarker levels and individual-level variables in the multivariable regression (Table S1 ) indicated that HTR1B predicted end-of-treatment P1NP levels (P = .03) but not end-of-treatment CTX levels (P = .17). HTTLPR expression was not related to CTX or P1NP.
Changes in Confounding Individual-Level Variables
Having a depressive episode that lasted longer than 2 years was associated with lower levels of P1NP at end of treatment. This effect of depression duration was explored ( Figure 2C) ; the mean decrease was 0.09 AE 0.25 lg/L (t(73) = À3.26, P = .002) in the 74 participants (44.6%) who had a current episode of depression lasting 2 or more years and 0.01 AE 0.24 lg/L (t(91) = À0.38, P = .70) for those with a current episode of less than 2 years.
DISCUSSION
How peripheral bone turnover markers changed during venlafaxine treatment was examined in this large sample of older adults with depression. The results indicate an association between duration of depression and P1NP levels and confirm previous findings. First, CTX, a marker of bone resorption, increased, and P1NP, a marker of bone formation, decreased with antidepressant treatment. This combination of bone turnover changes suggests accelerated bone loss. Second, antidepressant response was associated with CTX levels, which increased chiefly in nonremitters; in contrast, changes in P1NP were unrelated to remission status. Third, a polymorphism in the HTR1B gene predicted P1NP levels; participants with the low-expressing HTR1B genotype had a greater decrease in P1NP during the study. These important findings may help identify subgroups of individuals (based on treatment success, genotype, duration of depression) that may vary in bone turnover with antidepressant use. These results could help prevent morbidity from osteoporosis and osteopenia, which are common conditions in older adults, with prevalences of 16% and 48%, respectively; 26 any adjustment in the risk of these conditions is of public health importance. The current results identify factors that may enhance or mitigate this potential risk from SRIs. First, remission from depression may reduce the potential effect of SRIs on bone resorption; this generates the hypothesis that, when SRIs are not effective at treating depression, other treatment options (e.g., a switch to a non-SRI antidepressant rather than augmentation) might be favorable. This is important because antidepressants are typically prescribed chronically to older adults with depression, 27 and their use may be continued even when they are insufficiently effective. 28 Second, HTR1B genotype influenced P1NP change; this is consistent with the presence of 5-HT 1B receptors on osteoblasts and suggests that genetic testing could be used to assess risk of accelerated bone loss, or this receptor could be targeted using antidote strategies to reduce bone loss. Third, longer duration of current depression episode correlated with less bone formation. Individuals with chronic depression may be physiologically different from persons experiencing an acute episode. It has been proposed that individuals in a prolonged state of distress adapt physiologically or become resistant to ongoing stressors. 29 Thus, in individuals with chronic depression, treatment with an antidepressant may perturb the allostatic state that a person has physiologically learned to maintain.
The study has several limitations, and it does not confirm that SRI use accelerates bone loss in older adults. Although the findings suggest an association between bone loss and SRI treatment independent of depression, they should be considered preliminary data that argue for a larger randomized study to disentangle the effects of SRIs from the effects of depression itself in humans. First, this was a relatively small study. Second, the magnitude of changes in bone turnover markers (6-7%) was less than the minimum significant change in bone turnover markers for osteoporosis (12-23%), indicating that SRIs' effects on bone metabolism may be insufficiently robust to be of clinical significance. 30 Third, there was no control group, and it was not possible to exclude all possible confounders. Fourth, bone turnover markers, not actual bone loss, were measured; to measure bone loss would require a longer period of medication exposure (≥1 years to demonstrate changes in bone mineral density). Finally, only one medication was examined (venlafaxine), whose binding affinity is predominantly serotonergic, 13 which suggests that the findings are broadly applicable to SRIs in general, but research should be conducted to test other SRIs. In the absence of such confirmatory studies, the current data are insufficient to change the prescribing or labeling of SRIs for elderly adults and should not be taken as a recommendation to do so. Indeed, major depression in older adults is a disabling and often lethal illness, and SRIs are a mainstay of treatment for it. Strengths of this study include a well-characterized sample that received protocolized treatment. Depression was carefully diagnosed, and its severity was assessed using standardized instruments. Also, antidepressant concentrations were used to monitor adherence during the clinical trial. In contrast, the complex relationships between depression, risk of falls, bone mineral density, common side effects (e.g., dizziness), polypharmacy, and dosage and duration of antidepressant medications may have confounded the epidemiological data. 16 
CONCLUSION
This findings indicate that SRI use may be a risk factor for accelerated bone loss in older adults with depression by increasing osteoclast activity and reducing osteoblast activity. Randomized studies using bone mineral density testing are needed to clarify the risk:benefit ratio of these commonly prescribed medications and to determine whether some individual-level variables, such as treatment response, duration of depression, and genetic variability, may influence their risk.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Table S1 . Regression models predicting CTX and P1NP levels at the end-of-treatment venlafaxine trial.
Please note: Wiley-Blackwell is not responsible for the content, accuracy, errors, or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
